Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

NCT04082325 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Lu AF88434
DRUG: Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
DRUG: Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
DRUG: Placebo

Sponsor

H. Lundbeck A/S